menu
    • menu
    [{"orgOrder":0,"company":"SN BioScience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Irinotecan Hydrochloride","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"SN BioScience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SN BioScience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SN BioScience \/ Not Applicable"},{"orgOrder":0,"company":"SN BioScience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Irinotecan Hydrochloride","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"SN BioScience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SN BioScience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SN BioScience \/ Not Applicable"},{"orgOrder":0,"company":"SN BioScience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Irinotecan Hydrochloride","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"SN BioScience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SN BioScience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SN BioScience \/ Not Applicable"},{"orgOrder":0,"company":"SN BioScience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"7-Ethyl-10-Hydroxycamptothecin","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"SN BioScience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"SN BioScience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SN BioScience \/ Not Applicable"},{"orgOrder":0,"company":"SN BioScience","sponsor":"Boryeong","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cytotoxic Drug","year":"2023","type":"Licensing Agreement","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I","graph3":"SN BioScience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SN BioScience \/ Boryeong","highestDevelopmentStatusID":"6","companyTruncated":"SN BioScience \/ Boryeong"},{"orgOrder":0,"company":"SN BioScience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"7-Ethyl-10-Hydroxycamptothecin","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SN BioScience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SN BioScience \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SN BioScience \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by SN BioScience

    Menu

    SN BioScience

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SN BioScience

                            South Korea arrow
                            PharmScience R&D
                            Not Confirmed

                            SN BioScience

                            South Korea arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SN BioScience Propels SNB-101 to Phase 2 with IND Clearance from FDA

                            Details : SNB-101 (7-ethyl-10-hydroxycamptothecin) is a first nanoparticle formulation, an active metabolite of Irinotecan, being evaluated for the treatment of small cell lung cancer.

                            Product Name : SNB-101

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            January 10, 2025

                            Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SN BioScience

                            South Korea arrow
                            PharmScience R&D
                            Not Confirmed

                            SN BioScience

                            South Korea arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            EMA Grants Orphan Drug Designation for SNB-101 for Small Cell Lung Cancer

                            Details : SNB-101 (SN-38) is a first nanoparticle formulation of the anticancer drug SN-38. SN-38 is an active metabolite of Irinotecan, being evaluated for the treatment of small cell lung cancer.

                            Product Name : SNB-101

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 31, 2024

                            Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            SN BioScience

                            South Korea arrow
                            PharmScience R&D
                            Not Confirmed

                            SN BioScience

                            South Korea arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Irinotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            SN Bioscience Receives FDA Fast Track Designation for Small Cell Lung Cancer

                            Details : SNB-101 (SN-38) is the first nanoparticle formulation of the anticancer drug SN-38, being evaluated for the treatment of small cell lung cancer.

                            Product Name : SNB-101

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 09, 2024

                            Lead Product(s) : Irinotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            SN BioScience

                            South Korea arrow
                            PharmScience R&D
                            Not Confirmed

                            SN BioScience

                            South Korea arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Irinotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sn Bioscience Received US FDA Orphan Drug Designation for Snb-101 in Pancreatic Cancer

                            Details : SNB-101 (SN-38) is the world's first nanoparticle formulation of the anticancer drug SN-38, evaluated for treating pancreatic cancer using dual nano-micelle technology for delivery.

                            Product Name : SNB-101

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 29, 2024

                            Lead Product(s) : Irinotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            SN BioScience

                            South Korea arrow
                            PharmScience R&D
                            Not Confirmed

                            SN BioScience

                            South Korea arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Irinotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            US FDA Grants Orphan Drug Designation of SN Bioscience's Nano Anti-Cancer Drug 'SNB-101' for Small Cell Lung C...

                            Details : SNB-101 is the world's first product to use the active metabolite (SN-38) of Irinotecan as an API, and dual nano-micelle technology which is a core platform technology of SN Bioscience is applied.

                            Product Name : SNB-101

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 20, 2023

                            Lead Product(s) : Irinotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            SN BioScience

                            South Korea arrow
                            PharmScience R&D
                            Not Confirmed

                            SN BioScience

                            South Korea arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Boryeong

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            SN BioScience and Boryung Announce the Licensing Agreement on Generic Version of Abraxane

                            Details : Through this contract, Boryeong will have exclusive manufacturing and distribution rights in Korea for SNA-001. SNA-001 is a product that electrostatically binds cytotoxic anticancer drugs to albumin using albumin present in human blood as a drug carrier...

                            Product Name : SNA-001

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            January 26, 2023

                            Lead Product(s) : Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Boryeong

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth